QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data
uniQure (QURE) shares fell 37% after four-year Huntington’s gene therapy study results missed a key test, though three-year data showed significant slowing of disease decline. Analysts maintained bullish ratings, citing strong three-year results and potential FDA approval. The stock closed at $24.51, its worst day since November 2025.
How this was made
The 30-second read
Why it matters
The four‑year composite miss undermines confidence in long‑term durability, prompting a sharp price decline, but analysts still see value in the three‑year data and upcoming FDA filing.
Market read
First report of four‑year trial data causing a 37% stock plunge; traders must decide between short‑term risk and potential upside from perceived overreaction.
What to watch
Potential regulatory optimism and lack of approved Huntington's treatments could support a rebound.
Background
uniQure's AMT‑130 is a one‑time gene therapy for Huntington's disease, a condition with no approved disease‑modifying treatments.
Ticker impact
uniQure disclosed four-year Huntington's gene‑therapy data that missed a key statistical test, triggering a 37% share collapse.
downward pressure as the market prices in the composite miss, with possible short‑term bounce if traders view the sell‑off as excessive.
Trial data is a primary disclosure for a biotech; the sharp price drop indicates immediate reaction and heightened volatility.
Market effects
Highlights risk in gene‑therapy biotech sector; peers may see heightened scrutiny on trial durability.
Limited to US biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech community.
Counterpoint
The sell‑off may be overdone; the three‑year data remain robust, presenting a buying opportunity before FDA review.
Key entities
- companyuniQure
Biotech firm developing gene‑therapy AMT‑130 for Huntington's disease.
- analystStifel
Maintains Buy rating, citing robust three‑year results.